

REGISTER OF INTERESTS

SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Published:

29 November 2017

	Financial		Non-financial		Non-personal	Last updated	Action
	Specific	Non-Specific	Specific	Non-Specific			
CHAIR							
John Petrie, Professor of Diabetic Medicine	<p>Professor of Diabetic Medicine, University of Glasgow – Academic.</p> <p>Honorary Consultant Physician/ Diabetologist NHS GGC – Healthcare.</p> <p>Applied Clinical Intelligence – Adjudication Committee for Boehringer Ingelheim trials of empagliflozin in type 1 diabetes.</p> <p>Diabetologia – European diabetes journal (advisory board).</p> <p>Clinical Trial Committees (steering/adjudication /Glycemia) – Novo Nordisk, Sanofi,</p>	Shareholder – Lecht Ski Company.	<p>Trustee of Novo Nordisk UK Research Foundation (2008-2016).</p> <p>Chair Complications Clinical Studies Group, Diabetes UK (2016-2018).</p>	None	<p>Donation of medication for REMOVAL clinical trial (metformin in type 1 diabetes) of which I am Chief Investigator – Merck KGaA (Germany).</p> <p>Donation of reading services for endothelial function in REMOVAL trial (ENDOPAT) – Itamar Medical (Israel).</p> <p>Research Fellowship for Rachel Livingstone (2017-2020) – Novo Nordisk UK Research Foundation.</p> <p>Support for annual meeting of European Group for the study of Insulin Resistance – Novo Nordisk.</p> <p>RISC study 12 year follow-up grant to</p>	21.8.17	Agreed to not be allocated to questions on liraglutide or lixisenatide due to work on LEADER and ELIXA trials.

REGISTER OF INTERESTS

SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Published:

29 November 2017

	<p>Roche/Genentech, Quintiles/Janssen – approx. once monthly.</p> <p>Including membership of LEADER trial Global Expert Panel (2010-2016, Novo Nordisk) and ELIXA trial UK coordinator (2010-2014, Sanofi). These are the recent cardiovascular outcome trials with liraglutide and lixisenatide.</p> <p>Consultancy – Novo Nordisk, Servier, Lilly – approx. once every two months.</p> <p>Speaker – Novo Nordisk, Lilly, Boehringer – approx. once every two months.</p> <p>Now adjudication committee membership May</p>				<p>University of Pisa (2016-2017) – Janssen Pharmaceuticals.</p> <p>Grantholder: investigator-sponsored trial of empagliflozin in patients with diabetes and heart failure, Chief Investigator N Sattar (2016-2019) – Boehringer-Ingelheim.</p>		
--	---	--	--	--	---	--	--

REGISTER OF INTERESTS

SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Published:

29 November 2017

	2017 – Boehringer EMPEROR trials.						
	Pfizer.						
GUIDELINE DEVELOPMENT GROUP MEMBER							
Allan Cairns, (Patient Representative)	None – I am retired, no employer.	None	None	None	None	21.8.17	No action
Samantha Carmichael, (Lead Pharmacist)	Lead Pharmacist Clinical Trials/R&D – NHS Greater Glasgow and Clyde. Samantha Carmichael – self- employed locum pharmacist.	Travel and accommodation paid for participation in international meetings regarding clinical trials site perspectives – Fisher Clinical Services, 2–3 times per year. Chair of clinical Trials Specialist Interest Group for pharmacists & technicians in Scotland. Member of The National Pharmacy	None	None	None	21.8.17	No action

REGISTER OF INTERESTS

SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Published:

29 November 2017

		Clinical Trials Advisory Group (Royal Pharmaceutical Society Network).					
		Member of the Guild of Hospital Pharmacists.					
Gemma Currie, (Clinical Lecturer)	Clinical Lecturer, University of Glasgow – academic/clinical	None	None	None	None	21.8.17	No action
Andrea Llano, (ST5 in Clinical Pharmacology and Therapeutics)	ST5 in Clinical Pharmacology and Therapeutics, Department of Diabetes, Endocrinology & Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow.	None	None	None	None	21.8.17	No action
David McGrane, (Consultant Physician)	Consultant Physician, GGC Health Board – Provision of clinical expertise and management of patients within my	None	None	Member, Scottish South Asian Health Foundation	None	21.8.17	No clear conflict with individual products linked to guideline therefore no action.

REGISTER OF INTERESTS

SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Published:

29 November 2017

	<p>role as a Consultant Physician.</p> <p>Northview Consultancy Ltd – provision of advice and consultancy to pharmaceutical companies – once monthly.</p> <p>Advisory work, speaker at meetings, providing education – AZ, Boehringer Ingelheim, Janssen, Lilly, MSD, NAPP, Novo Novodisk, Sanofi, Takeda, Sunovion – on average once or twice monthly in total.</p>						
Gerard McKay, (Honorary Clinical Associate Professor)	<p>Consultant Physician NHS GG&C, Glasgow Royal Infirmary – health care provision including management of patients with diabetes.</p>	None	None	None	None	21.8.17	<p>Declaration of potential conflict (SGLT2 inhibitors). Discussion with all group members and agreement to continued work on this question in partnership with second group</p>

REGISTER OF INTERESTS

SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes

Published:

29 November 2017

	G McKay Medical Advisory Ltd – medical advisory, consultancy work (intermittently for companies including Novo Nordisk, BoehringerIngleheim, Sanofi, AZ, MSD, and Eli Lilly) This includes advising on a submission to SMC (Boehringer Ingleheim). – self and partner.						member. Independent review of pivotal decisions by HIS researcher with follow up to resolve queries revealed no anomalous decision.
May Millward, (Patient Representative)	Project Officer, Scottish Mediation Network – Professional body for accredited mediators in Scotland.	None	Chair of West Lothian Diabetes Scotland Group.	None	None	21.8.17	No action
Chris Schofield, (Consultant Physician)	Consultant Physician, NHS Tayside. Fee for travel, accommodation & conference – Alexion Pharmaceuticals, Single episode.	None	Site PI for Alexion Pharmaceuticals database for the study of hereditary hypohosphatatsia	None	None	21.8.17	No clear conflict with individual products linked to guideline therefore no action.